Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone

Jazz Pharmaceuticals plc

All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.
Chimerix's dordaviprone (NDA under Priority Review, PDUFA Aug 18, 2025) targets H3 K27M-mutant diffuse glioma.
If approved, dordaviprone could be first FDA-approved therapy for this rare brain tumor; eligible for Rare Pediatric Disease PRV.
Jazz expects to fund deal from existing cash; transaction projected to close in Q2 2025.
Chimerix board unanimously recommends shareholders tender shares; patent protection into 2037 with potential extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.